Aion Therapeutics Inc.
CSE: AION
Company Overview
Aion Therapeutics Inc. specializes in the development of combinatorial pharmaceuticals, nutraceuticals and cosmeceutical compounds from cannabis, psychedelic mushrooms, fungi, natural psychedelic formulations and other medicinal plants through its wholly owned subsidiary, AI Pharmaceuticals Jamaica Limited.
In addition, the company has a joint venture agreement with a private, vertically integrated licensed producer under the Cannabis Act to offer contract tolling extraction services to third-party businesses.
Financial Highlights
$0
Revenue (ttm)
-$1,500
Gross Profit (ttm)
-$0.06
Diluted EPS (ttm)
Management Team
Mr. Graham Simmonds
CEO, COO & Exec. Vice Chair of Board
Mr. Rakesh Malhotra B.Com., C.A., F.C.A., FCA (India), C.P.A., CPA, (U
Chief Financial Officer
Dr. Anthony J. Hall F.A.C.S., FAANS, M.D.
Medical Director & Independent Director
Ms. Patricia Purdy
Corp. Sec.
Mr. Paul Burke
Pres of AI Pharmaceuticals
Key Highlights
Market Capitalization
$114,128
Shares Outstanding
30,705,183
Shares Short (% of Float)
()
Insider Ownership
18%